Order results by:
| Issue | Title | |
| Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
| E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
| "... analysis of long-term consequences involved calculating the cost of pharmacotherapy and the costs ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic | Abstract similar documents |
| Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham | ||
| "... Pharma K.B. LLC, Russia). The average cost of the first prescribed regimen was 8,970.0 rubles/month ..." | ||
| Vol 15, No 3 (2022) | Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis | Abstract similar documents |
| А. V. Kukurika | ||
| "... level. In all cases, bedaquiline-based regimens represented a cost-effective alternative to previous ..." | ||
| Vol 14, No 2 (2021) | Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting | Abstract similar documents |
| E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov | ||
| "... with ixazomib) up to 8.03 million rubles (regimen with carfilzomib). The cost per hospitalization, depending ..." | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... the alternative treatment regimens by 34.5-229.5 thousand rubles or 13.12-50.14%. According to the cost ..." | ||
| Vol 8, No 2 (2015) | PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS | Abstract similar documents |
| Anton Alexandrovich Kasatkin | ||
| "... with the severity of the injury 31 points and made 11 000 and 5600 rubles. respectively. The cost of treating ..." | ||
| Vol 16, No 2 (2023) | Improving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025 | Abstract similar documents |
| V. V. Omelyanovskiy, I. A. Zheleznyakova, A. V. Zuev, O. S. Plakhotnik, O. A. Volkova, L. M. Davydova, G. V. Trifonova, E. V. Semakova, E. A. Prokhorovich, A. S. Volkova | ||
| "... ) in adults were published that did not contain interferon drug therapy regimens. Current therapy of chronic ..." | ||
| Vol 5, No 1 (2012) | COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko | ||
| "... Cost of illness is one of the basic methods of pharmacoeconomical estimation and in substance ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... per patient medication costs of using regorafenib are 255,000 rubles, which is 104,000 rubles less ..." | ||
| Vol 14, No 1 (2021) | Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District | Abstract similar documents |
| M. S. Soboleva, E. E. Loskutova | ||
| "... , perindopril+amlodipine+indapamide with a monthly cost over 500 rubles. Differences in the acquisition ..." | ||
| Vol 16, No 3 (2023) | Retrospective pharmacoeconomic study of antibiotic therapy in community-acquired pneumonia | Abstract similar documents |
| A. A. Taube, T. V. Alexandrova, O. A. Demidova, M. V. Zhuravleva | ||
| "... may depend on the age and comorbid conditions of patients. Objective: to analyze the costs ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... ) was used as the main criterion of effectiveness. Direct medical costs of drug therapy, and the costs ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer | Abstract similar documents |
| Yu. Yu. Petukhova, E. V. Eliseeva, M. V. Volkov, O. N. Li, A. G. Petukhova | ||
| "... with this disease. Material and methods. The authors performed a comparative cost-effectiveness analysis ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm | Abstract similar documents |
| M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov | ||
| "... by reducing the cost of drug therapy will be 1,251,698.99 rubles per 72 patients when comparing olokizumab ..." | ||
| Vol 14, No 2 (2021) | Medical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region | Abstract similar documents |
| A. D. Ermolaeva, V. S. Krysanova, T. N. Ermolaeva, K. I. Polyakova, K. A. Kokushkin | ||
| "... and drug dosage regimen indicated for patients with SA were used to calculate the relative cost weights (CW ..." | ||
| Vol 11, No 2 (2018) | Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer | Abstract similar documents |
| G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin | ||
| "... was more (30% on average) cost-efficient than the conventional regimen while both modalities produced ..." | ||
| Vol 8, No 4 (2015) | THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA | Abstract similar documents |
| K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva | ||
| "... .14 rubles, respectively). The cost per averted case of NE was 21 115 rubles within 35 days that is less than ..." | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic study of the treatment of arterial hypertension in children and adolescents using cost-of-illness analysis | Abstract similar documents |
| O. S. Mikhaylova, A. V. Krikova | ||
| "... Background. The cost-of-illness (COI) analysis allows to estimate and plan costs for calculations ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... , of which 1093 patients received “optimized basic regimen” (OBR) in accordance with the Federal Clinical ..." | ||
| Vol 10, No 2 (2017) | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov | ||
| "... (a difference of 24%). The average direct medical costs were 32,753 and 41,333 rubles per patient per year ..." | ||
| Vol 5, No 2 (2012) | THE ANALYSIS OF COST OF ILLNESS OF PREGNANT WOMEN WITH SYPHILIS | Abstract similar documents |
| A. I. Ovod, M. D. Mukovnina | ||
| Vol 16, No 4 (2023) | Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis C | Abstract similar documents |
| I. A. Narkevich, E. A. Tsitlionok | ||
| "... , costs per patient with F4 liver lesion were 398,464.73 rubles (45,16%, respectively). Conclusion ..." | ||
| Vol 12, No 3 (2019) | Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” | Abstract similar documents |
| S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva | ||
| "... Objective: to analyze whether comorbidity affects the cost of treatment and medical services ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract similar documents |
| D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
| "... vinorelbine saved 3,287,470.56 rubles for the budget fund considering the change in the cost of 1 mg ..." | ||
| Vol 11, No 2 (2018) | Clinical and economic efficiency of the loop ileostomy closure by various methods | Abstract similar documents |
| A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov | ||
| "... ,704.90 rubles. and 145,473.70 rubles, respectively, while in group 3, the cost was higher – 167,443,60 rubles (p ..." | ||
| Vol 16, No 4 (2023) | Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma | Abstract similar documents |
| S. K. Zyryanov, K. V. Orlova | ||
| "... a regimen with BRAF/MEK inhibitors as the first line and prolgolimab as the second line in adult patients ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... direct healthcare costs and incremental cost-effectiveness ratios (ICERs) per 1 life year gained were ..." | ||
| Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
| I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
| "... of follitropin alfa. The total costs for three cycles were 200,952.17 rubles with the use of follitropin delta ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... ,878.21 rubles, and the cost of one additionally saved QALY – 365,060.31 rubles. Conclusion. The WTPT ..." | ||
| Vol 10, No 2 (2017) | COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS | Abstract similar documents |
| M. B. Kubaeva, Y. Sh. Guchshina | ||
| "... The aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use ..." | ||
| Vol 17, No 4 (2024) | Development of a classification of anesthetic management methods and protocols for calculating financial costs | Abstract similar documents |
| D. V. Lukyantseva, J. A. Agafonova, V. V. Omelyanovskiy, S. A. Kovaleva, D. V. Fedyaev, I. N. Pasechnik, V. V. Schukin, D. S. Blinov, A. B. Abrosimov | ||
| "... Background. The costs of anesthetic support represent a significant and essential component ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... . The modeling was applied for cost minimization analyzis of using compared therapy regimens with comparable ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| "... », will reduce reduces costs relative to the current treatment regimen for 12,9 mil EUR (19,54%) or provide ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... ,415,036.25 and 3,676,115.43 rubles, respectively. Therefore, over the period of 2.5 years, the cost saving amounted ..." | ||
| Vol 8, No 1 (2015) | SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova | ||
| "... Study objective: to perform assessment of the social and economic burden (analysis of the cost ..." | ||
| Vol 17, No 4 (2024) | Standardized methodology for calculating the cost of medical care funded by government sources | Abstract similar documents |
| M. A. Sdvizhkova, S. A. Kovaleva, D. V. Fedyaev, V. V. Omelyanovskiy | ||
| "... . Efficient allocation of financial resources is becoming a priority. Calculating the cost of MC is considered ..." | ||
| Vol 17, No 4 (2024) | Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... Objective: to comparatively assess the weighted average costs associated with the use ..." | ||
| Vol 12, No 3 (2019) | Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings | Abstract similar documents |
| O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev | ||
| "... .82%. The average costs of treatments with AMA from group A were 15112.45 rubles, from group B – 24082.86 rubles ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... Objective: to evaluate cost-effectiveness and budget impact of using single and dual chamber ..." | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract similar documents |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| "... in patients with AF who had undergone PCI showed higher costs of the regimens containing NOACs with a presumed ..." | ||
| Vol 7, No 3 (2014) | THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT | Abstract similar documents |
| V. I. Ignatyeva, M. V. Avxentyeva | ||
| "... there are no uninamioulsly accepted methods and approaches for this type of research. The cost of illness method (assessment ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET | Abstract similar documents |
| R. I. Yagudina, V. G. Serpik | ||
| "... was 20,709 rubles. (Taking into account the costs of dialysis treatments), and for standard therapy - 110 ..." | ||
| Vol 10, No 2 (2017) | CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... costs of therapeutic regimens are shown. The discrepancy between the results of pharmacoeconomic ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... . It will provide avoiding 4.95 exacerbations, simultaneously with a reduction in total costs by 584,144 rubles ..." | ||
| Vol 18, No 2 (2025) | Pharmacoeconomic study of oral anticancer therapy: results of combined ABC/VEN and frequency analysis | Abstract similar documents |
| J. A. Agafonova | ||
| "... whose total cost accounted for 80% of all expenditures. Group C (the least expensive) comprised regimens ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... cancer (NSCLC). Materials and methods. The calculations included the direct costs of the healthcare ..." | ||
| Vol 16, No 3 (2023) | Clinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region | Abstract similar documents |
| A. D. Ermolaeva, T. N. Ermolaeva, K. A. Kokushkin | ||
| "... to determine the economic feasibility of quadritherapy, direct medical costs for the implemented technology ..." | ||
| Vol 18, No 2 (2025) | Clinical and economic evaluation of antibacterial therapy for nosocomial pneumonia on the example of a multidisciplinary hospital in Moscow | Abstract similar documents |
| D. D. Ivanova, I. N. Sychev, N. B. Lazareva | ||
| "... . The direct medical costs of empirical antibacterial therapy averaged for 9367 rubles (2118 rubles [1462; 3525 ..." | ||
| Vol 12, No 1 (2019) | Individual cost accounting in the management of medical organizations | Abstract similar documents |
| I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali | ||
| "... In the modern economic conditions, the rational planning of costs and the complex process ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... in additional 0.2657 LIGs or 0.2255 QALYs. The cost of 1 LIG was 213,4 thousand rubles, the cost of 1 QALY ..." | ||
| 1 - 50 of 249 Items | 1 2 3 4 5 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
